Allergic multimorbidity is associated with self-reported anaphylaxis in adults: A cross-sectional questionnaire study

Tuuli Thomander; Sanna Toppila-Salmi; Johanna Salimäki; Juha Jantunen; Heini Huhtala; Paula Pallasaho; Paula Kauppi

doi:10.1002/clt2.12184

Allergic multimorbidity is associated with self-reported anaphylaxis in adults: A cross-sectional questionnaire study

Tuuli Thomander^*
, Sanna Toppila-Salmi
, Johanna Salimäki
, Juha Jantunen
, Heini Huhtala
, Paula Pallasaho
, Paula Kauppi

^*Tämän työn vastaava kirjoittaja

Terveystieteet

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

5 Sitaatiot (Scopus)

11 Lataukset (Pure)

Abstrakti

Background: Anaphylaxis has increased over the last two decades in Europe, reaching an estimated prevalence of 0.3% and an incidence of 1.5–7.9 per 100,000 person-years. Allergic multimorbidity is associated with asthma severity, yet its role in anaphylaxis is not fully understood. Our aim was to study association between allergic multimorbidity and anaphylaxis in adults. Methods: We used population-based data from the Finnish Allergy Barometer Study (n = 2070, age range: 5–75). Food allergy (FA), atopic dermatitis (AD), allergic rhinitis (AR) and allergic conjunctivitis (AC), were defined from a self-completed questionnaire. A logistic regression adjusted on potential confounders (sex, age, smoking status) was applied to estimate the anaphylaxis risk associated with allergic multimorbidity. Results: 1319 adults with at least one allergic disease (FA, AD, AR, AC) with/without asthma (AS) were included. Of these, 164 had self-reported anaphylaxis [mean (SD, min-max) 54 (14, 22–75) years, 17% men]. AS, FA, AR, AC, or AD were reported by 86.0%, 62.2%, 82.3%, 43.3%, and 53.7% of subjects with anaphylaxis and respectively by 67.8%, 29.5%, 86.2%, 29.4%, and 34.4% of subjects without anaphylaxis. Compared with subjects exhibiting only one allergic disease, the risk of anaphylaxis increased with the number of allergic diseases; adjusted odds ratios (OR) [CI95%] for two, three, four and five coinciding allergic diseases were 1.80 [0.79–4.12], 3.35 [1.47–7.66], 7.50 [3.25–17.32], and 13.5 [5.12–33.09], respectively. The highest risk of anaphylaxis (6.47 [4.33–9.92]) was associated with FA + AS or their various variations with AR/AC/AD embodied, when compared with AR, AC, and AS separately or their combinations. Conclusions: Anaphylaxis was positively associated with the number of allergic diseases a subject exhibited and with subgroups including FA and/or AS. The results can be applied when estimating the risk of anaphylaxis for individual patients.

Alkuperäiskieli	Englanti
Artikkeli	e12184
Julkaisu	Clinical and Translational Allergy
Vuosikerta	12
Numero	7
DOI - pysyväislinkit	https://doi.org/10.1002/clt2.12184
Tila	Julkaistu - heinäk. 2022
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Rahoitus

Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti-Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of Väinö and Laina Kivi, the Ida-Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work. Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti‐Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of Väinö and Laina Kivi, the Ida‐Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work.

Julkaisufoorumi-taso

Jufo-taso 1

!!ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Pääsy asiakirjaan

10.1002/clt2.12184Lisenssi: CC BY

Clinical Translational All - 2022 - Thomander - Allergic multimorbidity is associated with selfreported anaphylaxis inFinal published version, 404 KBLisenssi: CC BY

https://urn.fi/URN:NBN:fi:tuni-202208096308Lisenssi: CC BY

Siteeraa tätä

@article{bb97a9c2e6ae4951bbc4a9abecfc048d,

title = "Allergic multimorbidity is associated with self-reported anaphylaxis in adults: A cross-sectional questionnaire study",

abstract = "Background: Anaphylaxis has increased over the last two decades in Europe, reaching an estimated prevalence of 0.3\% and an incidence of 1.5{\textendash}7.9 per 100,000 person-years. Allergic multimorbidity is associated with asthma severity, yet its role in anaphylaxis is not fully understood. Our aim was to study association between allergic multimorbidity and anaphylaxis in adults. Methods: We used population-based data from the Finnish Allergy Barometer Study (n = 2070, age range: 5{\textendash}75). Food allergy (FA), atopic dermatitis (AD), allergic rhinitis (AR) and allergic conjunctivitis (AC), were defined from a self-completed questionnaire. A logistic regression adjusted on potential confounders (sex, age, smoking status) was applied to estimate the anaphylaxis risk associated with allergic multimorbidity. Results: 1319 adults with at least one allergic disease (FA, AD, AR, AC) with/without asthma (AS) were included. Of these, 164 had self-reported anaphylaxis [mean (SD, min-max) 54 (14, 22{\textendash}75) years, 17\% men]. AS, FA, AR, AC, or AD were reported by 86.0\%, 62.2\%, 82.3\%, 43.3\%, and 53.7\% of subjects with anaphylaxis and respectively by 67.8\%, 29.5\%, 86.2\%, 29.4\%, and 34.4\% of subjects without anaphylaxis. Compared with subjects exhibiting only one allergic disease, the risk of anaphylaxis increased with the number of allergic diseases; adjusted odds ratios (OR) [CI95\%] for two, three, four and five coinciding allergic diseases were 1.80 [0.79{\textendash}4.12], 3.35 [1.47{\textendash}7.66], 7.50 [3.25{\textendash}17.32], and 13.5 [5.12{\textendash}33.09], respectively. The highest risk of anaphylaxis (6.47 [4.33{\textendash}9.92]) was associated with FA + AS or their various variations with AR/AC/AD embodied, when compared with AR, AC, and AS separately or their combinations. Conclusions: Anaphylaxis was positively associated with the number of allergic diseases a subject exhibited and with subgroups including FA and/or AS. The results can be applied when estimating the risk of anaphylaxis for individual patients.",

keywords = "allergic rhinitis, anaphylaxis, asthma, atopic dermatitis, food allergy",

author = "Tuuli Thomander and Sanna Toppila-Salmi and Johanna Salim{\"a}ki and Juha Jantunen and Heini Huhtala and Paula Pallasaho and Paula Kauppi",

note = "Funding Information: Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti-Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of V{\"a}in{\"o} and Laina Kivi, the Ida-Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work. Funding Information: Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti‐Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of V{\"a}in{\"o} and Laina Kivi, the Ida‐Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work. Publisher Copyright: {\textcopyright} 2022 The Authors. Clinical and Translational Allergy published by John Wiley \& Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.",

year = "2022",

month = jul,

doi = "10.1002/clt2.12184",

language = "English",

volume = "12",

journal = "Clinical and Translational Allergy",

issn = "2045-7022",

publisher = "John Wiley \& Sons",

number = "7",

}

TY - JOUR

T1 - Allergic multimorbidity is associated with self-reported anaphylaxis in adults

T2 - A cross-sectional questionnaire study

AU - Thomander, Tuuli

AU - Toppila-Salmi, Sanna

AU - Salimäki, Johanna

AU - Jantunen, Juha

AU - Huhtala, Heini

AU - Pallasaho, Paula

AU - Kauppi, Paula

N1 - Funding Information: Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti-Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of Väinö and Laina Kivi, the Ida-Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work. Funding Information: Tari Haahtela Professor Emeritus, Sirpa Peura Pharmacist, Previous Head of the Association of the Finnish Pharmacies and all the study participants. The study was funded by The Finnish National Allergy Programme and the Association of Finnish Pharmacies. TT: This study was supported by the Foundation of the Finnish Anti‐Tuberculosis Association, The Research Foundation of the Pulmonary Diseases, the Research Foundation of Väinö and Laina Kivi, the Ida‐Montini Foundation, the Finnish Society of Allergology and Immunology and the Finnish Medical Foundation. These personal grants did not affect the content of the study. STS reports consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma, and Roche Products and a grant from GSK, outside the submitted work. Publisher Copyright: © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

PY - 2022/7

Y1 - 2022/7

N2 - Background: Anaphylaxis has increased over the last two decades in Europe, reaching an estimated prevalence of 0.3% and an incidence of 1.5–7.9 per 100,000 person-years. Allergic multimorbidity is associated with asthma severity, yet its role in anaphylaxis is not fully understood. Our aim was to study association between allergic multimorbidity and anaphylaxis in adults. Methods: We used population-based data from the Finnish Allergy Barometer Study (n = 2070, age range: 5–75). Food allergy (FA), atopic dermatitis (AD), allergic rhinitis (AR) and allergic conjunctivitis (AC), were defined from a self-completed questionnaire. A logistic regression adjusted on potential confounders (sex, age, smoking status) was applied to estimate the anaphylaxis risk associated with allergic multimorbidity. Results: 1319 adults with at least one allergic disease (FA, AD, AR, AC) with/without asthma (AS) were included. Of these, 164 had self-reported anaphylaxis [mean (SD, min-max) 54 (14, 22–75) years, 17% men]. AS, FA, AR, AC, or AD were reported by 86.0%, 62.2%, 82.3%, 43.3%, and 53.7% of subjects with anaphylaxis and respectively by 67.8%, 29.5%, 86.2%, 29.4%, and 34.4% of subjects without anaphylaxis. Compared with subjects exhibiting only one allergic disease, the risk of anaphylaxis increased with the number of allergic diseases; adjusted odds ratios (OR) [CI95%] for two, three, four and five coinciding allergic diseases were 1.80 [0.79–4.12], 3.35 [1.47–7.66], 7.50 [3.25–17.32], and 13.5 [5.12–33.09], respectively. The highest risk of anaphylaxis (6.47 [4.33–9.92]) was associated with FA + AS or their various variations with AR/AC/AD embodied, when compared with AR, AC, and AS separately or their combinations. Conclusions: Anaphylaxis was positively associated with the number of allergic diseases a subject exhibited and with subgroups including FA and/or AS. The results can be applied when estimating the risk of anaphylaxis for individual patients.

AB - Background: Anaphylaxis has increased over the last two decades in Europe, reaching an estimated prevalence of 0.3% and an incidence of 1.5–7.9 per 100,000 person-years. Allergic multimorbidity is associated with asthma severity, yet its role in anaphylaxis is not fully understood. Our aim was to study association between allergic multimorbidity and anaphylaxis in adults. Methods: We used population-based data from the Finnish Allergy Barometer Study (n = 2070, age range: 5–75). Food allergy (FA), atopic dermatitis (AD), allergic rhinitis (AR) and allergic conjunctivitis (AC), were defined from a self-completed questionnaire. A logistic regression adjusted on potential confounders (sex, age, smoking status) was applied to estimate the anaphylaxis risk associated with allergic multimorbidity. Results: 1319 adults with at least one allergic disease (FA, AD, AR, AC) with/without asthma (AS) were included. Of these, 164 had self-reported anaphylaxis [mean (SD, min-max) 54 (14, 22–75) years, 17% men]. AS, FA, AR, AC, or AD were reported by 86.0%, 62.2%, 82.3%, 43.3%, and 53.7% of subjects with anaphylaxis and respectively by 67.8%, 29.5%, 86.2%, 29.4%, and 34.4% of subjects without anaphylaxis. Compared with subjects exhibiting only one allergic disease, the risk of anaphylaxis increased with the number of allergic diseases; adjusted odds ratios (OR) [CI95%] for two, three, four and five coinciding allergic diseases were 1.80 [0.79–4.12], 3.35 [1.47–7.66], 7.50 [3.25–17.32], and 13.5 [5.12–33.09], respectively. The highest risk of anaphylaxis (6.47 [4.33–9.92]) was associated with FA + AS or their various variations with AR/AC/AD embodied, when compared with AR, AC, and AS separately or their combinations. Conclusions: Anaphylaxis was positively associated with the number of allergic diseases a subject exhibited and with subgroups including FA and/or AS. The results can be applied when estimating the risk of anaphylaxis for individual patients.

KW - allergic rhinitis

KW - anaphylaxis

KW - asthma

KW - atopic dermatitis

KW - food allergy

U2 - 10.1002/clt2.12184

DO - 10.1002/clt2.12184

M3 - Article

AN - SCOPUS:85134667200

SN - 2045-7022

VL - 12

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

IS - 7

M1 - e12184

ER -

Allergic multimorbidity is associated with self-reported anaphylaxis in adults: A cross-sectional questionnaire study

Abstrakti

Rahoitus

Julkaisufoorumi-taso

!!ASJC Scopus subject areas

Pääsy asiakirjaan

Sormenjälki

Siteeraa tätä